Figure 4
Figure 4. Apoptosis and colony growth assays in full-length Ikaros- and Ik6-expressing cells after treatment with TKIs. (A) Apoptotic rates of untreated and TKI (imatinib, nilotinib, and dasatinib)-treated cells. Treatment with TKIs increased the apoptotic rate in Ikaros full-length expressing cells (SD-1), whereas no differences were identified in Ik6 expressing cells (BV-173) between untreated and TKI-treated cells. (B) Mean value of colony growth from SD-1 and BV-173 cell lines in control cells (untreated) and after incubation with imatinib, nilotinib, and dasatinib.

Apoptosis and colony growth assays in full-length Ikaros- and Ik6-expressing cells after treatment with TKIs. (A) Apoptotic rates of untreated and TKI (imatinib, nilotinib, and dasatinib)-treated cells. Treatment with TKIs increased the apoptotic rate in Ikaros full-length expressing cells (SD-1), whereas no differences were identified in Ik6 expressing cells (BV-173) between untreated and TKI-treated cells. (B) Mean value of colony growth from SD-1 and BV-173 cell lines in control cells (untreated) and after incubation with imatinib, nilotinib, and dasatinib.

Close Modal

or Create an Account

Close Modal
Close Modal